UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Genetic Control of MTOR to Improve Adoptive T Cell Therapy of Tumours

Zech, MH; (2014) Genetic Control of MTOR to Improve Adoptive T Cell Therapy of Tumours. Doctoral thesis , UCL (University College London). Green open access

[thumbnail of Thesis MZ 2014 edited version.pdf] PDF
Thesis MZ 2014 edited version.pdf
Available under License : See the attached licence file.

Download (4MB)

Abstract

Adoptive T cell therapy to treat cancer in combination with re-directing specificity through T cell receptor (TCR) gene transfer, represents an effective therapeutic option. However, reduced effector responses due to the immunosuppressive tumour microenvironment and insufficient long-term engraftment of transferred cells represent two potential limitations. Tumours often employ mechanisms to inhibit T cell responses including secretion of TGFβ and depleting the tumour microenvironment of amino acids. The main aim of this PhD project was to develop a strategy to enhance T cell function for tumour therapy. The mammalian target of rapamycin (mTOR) pathway regulates CD8 T cell differentiation such that high mTOR activation leads to enhanced effector whilst low mTOR activation leads to increased T cell memory formation. Two retrovirus constructs have been designed whereby one expresses the positive mTOR regulator Rheb and the other expresses the negative mTOR regulator Pras40. Rheb transduction into CD8 T cells resulted in enhanced activation of mTOR, increased effector functions and partial resistance to TGFβ and low arginine concentrations. Pras40 overexpression led to a decrease in the activation of mTOR and reduced effector functions. Rheb transduced CD8 T cells expanded efficiently upon antigen encounter in vivo, followed by pronounced T cell contraction. Pras40 transduced T cells were unable to expand in vivo, but persisted at low numbers and acquired a central memory phenotype. Tumour bearing mice treated with TCR re-directed CD8 T cells transduced with Rheb showed improved tumour protection. Pras40 overexpression resulted in the loss of the protective function of TCR re-directed T cells. Together, the data show that gene transfer can be used to regulate mTOR activity in T cells. Enhancing mTOR activity led to improved tumour control despite reducing memory formation. Permanent mTOR inhibition, on the other hand, preserved some memory characteristcs of T cells but deteriorated their tumour protective functions.

Type: Thesis (Doctoral)
Title: Genetic Control of MTOR to Improve Adoptive T Cell Therapy of Tumours
Open access status: An open access version is available from UCL Discovery
Language: English
Additional information: Third party copyright material has been removed from ethesis.
Keywords: tumour immunology, adoptive cell therapy, ACT, memory T cell, effector T cell, mTOR, Rheb, Pras40
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
URI: https://discovery.ucl.ac.uk/id/eprint/1420953
Downloads since deposit
842Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item